These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
619 related articles for article (PubMed ID: 24844595)
1. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595 [TBL] [Abstract][Full Text] [Related]
2. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879 [TBL] [Abstract][Full Text] [Related]
3. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis. Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754 [TBL] [Abstract][Full Text] [Related]
5. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas. Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215 [TBL] [Abstract][Full Text] [Related]
6. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing. Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma. Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767 [TBL] [Abstract][Full Text] [Related]
15. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations. Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482 [TBL] [Abstract][Full Text] [Related]
16. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. Bakhsh S; Kinloch M; Hoang LN; Soslow RA; Köbel M; Lee CH; McAlpine JN; McConechy MK; Gilks CB Histopathology; 2016 May; 68(6):916-24. PubMed ID: 26416160 [TBL] [Abstract][Full Text] [Related]
17. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features. Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522 [TBL] [Abstract][Full Text] [Related]
18. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis. Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355 [TBL] [Abstract][Full Text] [Related]